The psychedelic sector never sits still. Here is what happened during the week of June 1–7, 2026, and why each story matters for the companies and investors we track.
Optimi Health Corp. (OPTH): Optimi Health completes commercial GMP psilocybin production run
Optimi Health completed a GMP production run of its 5mg psilocybin finished drug product, with output destined for commercial treatment-resistant depression prescriptions in Australia plus planned clinical trials in the U.S. and Europe. All stages, from biomass cultivation and API extraction to encapsulation and packaging, were done in-house under its Health Canada Drug Establishment Licence. The company also updated its bottling configuration for prescriber and patient ease of use, underscoring its vertically integrated manufacturing capacity.
Source: newswire.ca
Bright Minds Biosciences Inc. (DRUG): Bright Minds Biosciences presents at Jefferies Global Healthcare Conference
Bright Minds Biosciences presented at the Jefferies Global Healthcare Conference, giving management a platform to update investors on its selective serotonin (5-HT2C) agonist pipeline targeting epilepsy and neuropsychiatric disorders. Conference visibility is meaningful for the small-cap developer, which has drawn heightened sell-side attention in 2026. The appearance is part of ongoing investor-outreach efforts around its lead clinical programs.
Source: stocktitan.net
That's the recap. Follow the Psychedelic Invest Index for how the sector is trading, and check back next week for the next edition.